Gaslightwala Abizer 4

What Happened
Abizer Gaslightwala, CEO and director of Akari Therapeutics plc (AKTX), reported acquiring two derivative awards on June 24, 2026: 5,500 American Depositary Shares (ADS) through the vesting of a previously granted option, and a separate grant of 15,563 ADS. Both entries show an acquisition price of $0.00 (derivative awards), for a total of 21,063 ADS acquired on that date. These were reported on a Form 4 filed June 25, 2026.

Key Details

• Transaction date: 2026-06-24; Form 4 filed: 2026-06-25 (timely filing).
• Reported items: 5,500 ADS acquired @ $0.00 (vested portion of an earlier option); 15,563 ADS acquired @ $0.00 (grant). Total = 21,063 ADS (derivative).
• Shares owned after transaction: not specified in the filing.
• Footnote (F1): On April 1, 2026 the reporting person was granted an option to purchase 15,000 ADS. That option vests in three installments tied to qualified financings of at least $15,000,000 (in gross proceeds) on or before June 30, 2026. The issuer closed a qualified financing of $5,500,000, which caused the option to vest as to 5,500 ADS.
• Filing timeliness: filing appears timely (filed the day after the report date). No 10b5-1, tax withholding, or late-filing indications were included.

Context
These entries are derivative awards (vests/grants), not open-market purchases or sales — they do not reflect an immediate cash payment or proceeds. The 5,500 ADS reported were a vesting from a previously granted option; the remaining option vesting is contingent on additional qualified financings per the footnote. The filing also states each ADS in that option context represents 80,000 ordinary shares (per the footnote), meaning conversion into underlying ordinary shares would follow the ADS conversion ratio and any applicable restrictions.